[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"app-context":3,"blog-abbvie-slips-behind-rivals-as-lutikizumab-hits-31-4-response-in-hs-trial-KO":222},{"languages":4,"categories":41,"products":125,"competitors":149},[5,9,13,17,21,25,29,33,37],{"name":6,"code":7,"id":8},"English","EN","TGFuZ3VhZ2U6ZW4=",{"name":10,"code":11,"id":12},"Español","ES","TGFuZ3VhZ2U6ZXM=",{"name":14,"code":15,"id":16},"Português","PT","TGFuZ3VhZ2U6cHQ=",{"name":18,"code":19,"id":20},"日本語","JA","TGFuZ3VhZ2U6amE=",{"name":22,"code":23,"id":24},"한국어","KO","TGFuZ3VhZ2U6a28=",{"name":26,"code":27,"id":28},"Deutsch","DE","TGFuZ3VhZ2U6ZGU=",{"name":30,"code":31,"id":32},"Italiano","IT","TGFuZ3VhZ2U6aXQ=",{"name":34,"code":35,"id":36},"Français","FR","TGFuZ3VhZ2U6ZnI=",{"name":38,"code":39,"id":40},"中文 (中国)","ZH","TGFuZ3VhZ2U6emg=",[42,73,104],{"icon":43,"slug":44,"title":45,"description":46,"featuredLinks":47},"mingcute:stock-line","stock-market-basics","Stock Market Basics","\u003Cp>Beginners' guides and practical tips for understanding stock market investing.\u003C\u002Fp>\n",[48,53,58,63,68],{"url":49,"title":50,"description":51,"ogImage":52},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-makes-stocks-go-up-and-down","What Makes Stocks Go Up and Down | TIKR.com","Understanding what makes stock prices go up and down can help investors better navigate investing. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-makes-stocks-go-up-and-down-banner\u002FWhat-makes-stocks-go-up-and-down-banner.jpg?_i=AA",{"url":54,"title":55,"description":56,"ogImage":57},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fdividend-yield-meaning-formula-example","Dividend Yield: Meaning, Formula, Example | Tikr.com Blog | TIKR.com","The dividend yield is a key metric for investors looking to gauge the income potential of their investments. It measures how much a company pays out in","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FDividend-yield\u002FDividend-yield.png?_i=AA",{"url":59,"title":60,"description":61,"ogImage":62},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fmarket-capitalization-definition-formula-and-why-it-matters","Market Capitalization: Definition, Formula, and Why It Matters | TIKR.com","Long-term investors often look at various valuation metrics when deciding whether to invest in a particular company. One helpful metric to evaluate is","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters.png?_i=AA",{"url":64,"title":65,"description":66,"ogImage":67},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fearnings-per-share-definition-formula-and-why-eps-matters","Earnings Per Share: Definition, Formula, and Why EPS Matters | TIKR.com","Earnings Per Share (EPS) represents the portion of a company's net earnings allocated to each share. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEPS-Defiinition-formula-and-why-EPS-matters-1\u002FEPS-Defiinition-formula-and-why-EPS-matters-1.png?_i=AA",{"url":69,"title":70,"description":71,"ogImage":72},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-stock-price-target","What Is a Stock Price Target? | TIKR.com","A price target is a stock's estimated future price. It can help investors quickly find undervalued stocks. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-Stock-Price-Target-2\u002FWhat-is-a-Stock-Price-Target-2.png?_i=AA",{"icon":74,"slug":75,"title":76,"description":77,"featuredLinks":78},"material-symbols:analytics-outline","fundamental-analysis","Fundamental Analysis","\u003Cp>In-depth resources and financial metrics to help you evaluate companies like a pro.\u003C\u002Fp>\n",[79,84,89,94,99],{"url":80,"title":81,"description":82,"ogImage":83},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fshare-repurchase-why-do-companies-buy-back-their-stock","Share Repurchase: Why Do Companies Buy Back Their Stock? | TIKR.com","Share repurchases, or share buybacks, have gained popularity in the last two decades. According to a report from Goldman Sachs, stock buybacks initiated","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e.png?_i=AA",{"url":85,"title":86,"description":87,"ogImage":88},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-invested-capital","What Is a Good Return on Invested Capital? | TIKR.com","Learning about Return on Invested Capital (ROIC) can help investors spot highly profitable stocks that can drive long-term returns. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-Invested-capital\u002FWhat-is-a-good-return-on-Invested-capital.png?_i=AA",{"url":90,"title":91,"description":92,"ogImage":93},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-equity-ratio","What is a Good Return on Equity Ratio | Tikr.com Blog | TIKR.com","Return on Equity (ROE) is a financial ratio that reflects a company's profitability in relation to the equity invested by shareholders. It basically","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-equity-ratio-1\u002FWhat-is-a-good-return-on-equity-ratio-1.jpg?_i=AA",{"url":95,"title":96,"description":97,"ogImage":98},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-p-e-ratio","What Is a Good P\u002FE Ratio? | TIKR.com","Financial analysts and investors look at various metrics before deciding whether a stock is a buy. One of the metrics is the price-to-earnings ratio (P\u002FE","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-PE-ratio-1\u002FWhat-is-a-good-PE-ratio-1.jpg?_i=AA",{"url":100,"title":101,"description":102,"ogImage":103},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Ftop-6-metrics-for-investing-in-reits","Top 6 Metrics for Investing in REITs | TIKR.com","Real estate has been one of the greatest asset classes for wealth creation in history, and investing in Real Estate Investment Trusts (REITs) can allow","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FGroup-10\u002FGroup-10.png?_i=AA",{"icon":105,"slug":106,"title":107,"description":108,"featuredLinks":109},"hugeicons:investigation","investing-lingo","Investing Lingo","\u003Cp>A comprehensive glossary of investing terms and jargon so you can speak the language of the markets confidently.\u003C\u002Fp>\n",[110,115,120],{"url":111,"title":112,"description":113,"ogImage":114},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fenterprise-value-definition-and-calculation","Enterprise Value: Definition and Calculation | Tikr.com Blog | TIKR.com","Enterprise value (EV) is a financial metric that offers a comprehensive snapshot of a company's total value. Unlike market capitalization which solely","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEnterprise-Value-Definition-and-Calculation_37576e40\u002FEnterprise-Value-Definition-and-Calculation_37576e40.png?_i=AA",{"url":116,"title":117,"description":118,"ogImage":119},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Febitda-definition-formula-how-to-use-it","EBITDA: Definition, Formula, How to Use It | TIKR.com","EBITDA stands for earnings before interest, taxes, depreciation and amortization. It's a financial metric commonly used to evaluate a company's financial","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEBITDA-Definition-Formula-How-to-Use-It\u002FEBITDA-Definition-Formula-How-to-Use-It.png?_i=AA",{"url":121,"title":122,"description":123,"ogImage":124},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-the-free-cash-flow-formula-and-why-does-it-matter","What is the Free Cash Flow Formula and Why Does It Matter | TIKR.com","Free cash flow, or FCF, is the cash a company generates after it accounts for outflows required to maintain business operations and support capital","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-the-free-cash-flow-formula\u002FWhat-is-the-free-cash-flow-formula.png?_i=AA",[126,130,134,137,141,145],{"slug":127,"modified":128,"title":129},"valuation-model-builder","2025-07-03T00:18:53","Value Stocks Quickly and Accurately",{"slug":131,"modified":132,"title":133},"stock-portfolio-tracking","2024-12-02T22:21:28","Monitor Your Portfolio",{"slug":75,"modified":135,"title":136},"2025-01-21T22:10:52","Instantly Analyze Companies with In-Depth Metrics",{"slug":138,"modified":139,"title":140},"stock-screener","2024-12-02T22:13:31","Find the Best Stocks to Buy",{"slug":142,"modified":143,"title":144},"investor-stock-portfolio","2025-01-21T22:02:56","Follow Investment Moves of Top Investors",{"slug":146,"modified":147,"title":148},"analyze-stocks","2025-07-23T16:04:24","Analyze Stocks",[150,154,158,162,166,170,174,178,182,186,190,194,198,202,206,210,214,218],{"slug":151,"title":152,"modified":153},"bloomberg","Bloomberg","2025-01-16T14:23:44",{"slug":155,"title":156,"modified":157},"morningstar","Morningstar","2025-01-16T14:25:16",{"slug":159,"title":160,"modified":161},"sentieo","Sentieo","2025-01-16T17:58:27",{"slug":163,"title":164,"modified":165},"googlefinance","Google Finance","2025-01-17T19:39:37",{"slug":167,"title":168,"modified":169},"tradingview","TradingView","2025-01-16T18:17:01",{"slug":171,"title":172,"modified":173},"factset","Factset","2025-01-16T18:20:16",{"slug":175,"title":176,"modified":177},"finviz","Finviz","2025-01-16T18:23:40",{"slug":179,"title":180,"modified":181},"ycharts","YCharts","2025-01-16T18:32:19",{"slug":183,"title":184,"modified":185},"marketbeat","MarketBeat","2025-03-11T00:27:23",{"slug":187,"title":188,"modified":189},"benzinga","Benzinga","2025-03-11T00:31:00",{"slug":191,"title":192,"modified":193},"gurufocus","Gurufocus","2025-03-11T00:31:12",{"slug":195,"title":196,"modified":197},"fast-graphs","FAST Graphs","2025-03-11T00:31:19",{"slug":199,"title":200,"modified":201},"tipranks","TipRanks","2025-03-11T00:31:26",{"slug":203,"title":204,"modified":205},"seeking-alpha","Seeking Alpha","2025-03-11T00:31:45",{"slug":207,"title":208,"modified":209},"thestreet","TheStreet","2025-03-11T00:31:52",{"slug":211,"title":212,"modified":213},"investing-com","Investing.com","2025-03-11T00:32:00",{"slug":215,"title":216,"modified":217},"zacks","Zacks","2025-03-26T15:40:40",{"slug":219,"title":220,"modified":221},"alphasense","AlphaSense","2025-03-11T00:32:15",{"post":223,"seo":259,"relatedPosts":265,"suggestedPosts":344},{"id":224,"title":225,"date":226,"modified":227,"excerpt":228,"content":229,"wordCount":230,"lang":231,"uri":232,"slug":233,"cloudinaryAssetId":234,"featuredImageOriginalUrl":235,"featuredImageMetadata":236,"author":239,"editor":245,"categories":250,"relatedPosts":256,"seo":257},143739,"AbbVie, HS 시험에서 Lutikizumab 반응률 31.4% 기록하며 경쟁사에 뒤처져","2026-10-23T13:50:00","2026-10-22T20:17:11","\u003Cp>AbbVie의 루티키주맙이 화농성 한선염(Hidradenitis Suppurativa)에서 3상 목표를 달성했지만, 위약 대비 8포인트 차이는 기대에 미치지 못했습니다.\u003C\u002Fp>","\u003Ch3 id=\"h-key-takeaways\" class=\"wp-block-heading\">주요 요점\u003C\u002Fh3>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>애브비의 루티키주맙이 화농성 한선염에 대한 3상 임상 목표를 달성했으며, 16주차에 위약 대비 31.4%의 환자가 HiSCR75를 달성했습니다(위약군 23.4%).\u003C\u002Fli>\n\n\n\n\u003Cli>8포인트라는 얇은 격차는 경쟁사 문레이크의 주가를 상승시키고, 유사 경로를 표적하는 아발로의 주가를 급락시켰습니다.\u003C\u002Fli>\n\n\n\n\u003Cli>주가는 스카이리지와 린보크 성장으로 6개월간 40.7%의 총 수익률을 기록한 후, 시장 평균 목표가인 $283.50보다 약간 높은 $285 근처에 머물고 있습니다.\u003C\u002Fli>\n\n\n\n\u003Cli>10월 30일 발표될 3분기 실적은 면역학 부문의 성장세가 매출 가이던스를 계속 상향 조정하게 할지 보여줄 것입니다.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">\u003Cstrong>애브비 (\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?fid=1&ref=meufz8&cid=141885706&tid=225079155\">ABBV\u003C\u002Fa>)\u003C\u002Fstrong>는 목요일 3상 임상에서 승리했고, 그 경쟁사들이 축하 파티를 열었습니다.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">화농성 한선염 치료제인 애브비의 IL-1α\u002Fβ 항체 루티키주맙이 1차 평가변수를 달성했습니다. 하지만 위약 대비 차이가 얇았기 때문에 경쟁 우려가 완화되며 \u003Cstrong>문레이크 면역치료제 (\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?fid=1&ref=meufz8&cid=713684532&tid=1769715609\">MLTX\u003C\u002Fa>)\u003C\u002Fstrong>가 급등한 반면, 유사 경로를 표적하는 \u003Cstrong>아발로 테라퓨틱스 (\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?fid=1&ref=meufz8&cid=145313032&tid=316866598\">AVTX\u003C\u002Fa>)\u003C\u002Fstrong>는 급락했습니다.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">애브비 자체는 거의 움직이지 않으며 $285 근처에서 거래되고 있습니다. 이 침착함은 현재 이 주가를 실제로 움직이는 요인이 무엇인지에 대해 많은 것을 말해줍니다.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">이는 또한 가치 평가에 대한 질문을 제기합니다. 주가는 6개월간 40.7%의 총 수익률을 기록한 후, $283.50의 시장 평균 목표가보다 약간 위에 위치하고 있습니다.\u003C\u002Fp>\n\n\n\n\u003Ch3 class=\"wp-block-heading\">8포인트의 차이\u003C\u002Fh3>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">INTREPID 연구의 주요 수치는 다음과 같습니다:\u003C\u002Fp>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>주간 루티키주맙을 투여받은 환자의 31.4%가 16주차에 HiSCR75를 달성\u003C\u002Fli>\n\n\n\n\u003Cli>위약군은 23.4%가 달성\u003C\u002Fli>\n\n\n\n\u003Cli>더 적은 발작, 더 나은 통증 점수 및 위약 수준의 안전성 프로필\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">위약 대비 8포인트의 이득은 통계적 기준을 통과합니다. 그러나 혼잡한 HS 시장에서 많은 투자자들이 기대했던 수준에는 미치지 못합니다. \u003Ca href=\"https:\u002F\u002Fnews.abbvie.com\u002F2024-01-08-Lutikizumab-Showed-Positive-Results-in-a-Phase-2-Trial-of-Adults-with-Moderate-to-Severe-Hidradenitis-Suppurativa-as-Program-Advances-to-Phase-3\">2상 임상\u003C\u002Fa>에서는 항-TNF 치료에 실패한 환자들을 대상으로 했지만, 고용량 군에서 위약군 17.5% 대비 최대 45.9%의 HiSCR75 달성률을 보였습니다.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">애브비는 36주 연장 데이터를 사용하여 2027년 하반기에 허가 신청을 계획하고 있습니다. 또한 체중 감량 치료제와 함께 이 약물을 테스트할 계획입니다.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">문레이크와 아발로는 올해 모든 HS 관련 뉴스에 반응하며 거래되었으며, 이번 소식도 그 중 하나입니다…\u003C\u002Fp>\n\n\n\n\u003Cfigure class=\"wp-block-image size-full\">\u003Cimg width=\"3026\" height=\"2017\" data-public-id=\"images\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return.webp\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_3026,h_2017,c_scale\u002Ff_webp,q_auto\u002Fv1792700033\u002Fimages\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return.webp?_i=AA\" alt=\"\" class=\"wp-post-143739 wp-image-143902\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1792700033\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1792700033\u002Fimages\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return.webp?_i=AA 3026w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_767,h_511,c_scale\u002Ff_webp,q_auto\u002Fv1792700033\u002Fimages\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return.webp?_i=AA 767w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1536,h_1024,c_scale\u002Ff_webp,q_auto\u002Fv1792700033\u002Fimages\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return.webp?_i=AA 1536w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_2048,h_1365,c_scale\u002Ff_webp,q_auto\u002Fv1792700033\u002Fimages\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return.webp?_i=AA 2048w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792700033\u002Fimages\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return.webp?_i=AA 600w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1199,h_799,c_scale\u002Ff_webp,q_auto\u002Fv1792700033\u002Fimages\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return.webp?_i=AA 1199w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1400,h_933,c_scale\u002Ff_webp,q_auto\u002Fv1792700033\u002Fimages\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return.webp?_i=AA 1400w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_299,h_199,c_scale\u002Ff_webp,q_auto\u002Fv1792700033\u002Fimages\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return\u002FTIKR.com_AbbVie-Inc.-ABBV-Total-Return.webp?_i=AA 299w\" sizes=\"auto, (max-width: 3026px) 100vw, 3026px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">애브비 (ABBV): 총 수익률 (%) 대 문레이크 면역치료제 및 아발로 테라퓨틱스, 지난 1년 (\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">TIKR\u003C\u002Fa>\u003C\u002Fstrong>)\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">애브비의 주가 흐름은 HS 뉴스에 거의 반응하지 않는 반면, 두 개의 소형 기업 주가는 이에 크게 요동칩니다.\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\">스카이리지와 린보크가 여전히 주도합니다\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">루티키주맙은 항상 사이드 디시였습니다. 메인 코스는 \u003Ca href=\"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fskyrizi-just-hit-4-5-billion-in-a-single-quarter-abbvies-humira-problem-is-solved\">스카이리지와 린보크\u003C\u002Fa>입니다.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">2분기에 매출은 10.2% 증가한 $169.9억 달러, 조정 EPS는 22.9% 증가한 $3.65를 기록했습니다. 면역학 부문은 15.1% 성장하여 $87.9억 달러를 기록했으며, 스카이리지는 $55.1억 달러, 린보크는 $25.3억 달러로 각각 약 24% 증가했습니다.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">경영진은 올해 두 번째로 2026년 매출 가이던스를 $3억 달러 상향 조정하여 $672억 달러에서 $682억 달러로 수정했습니다. 애브비는 또한 스카이리지와 린보크가 성숙기에 접어들면서 장기 지속형 면역학 자산을 추가하기 위해 \u003Cstrong>아포지 테라퓨틱스 (\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?fid=1&ref=meufz8&cid=1816591253&tid=1845753306\">APGE\u003C\u002Fa>)\u003C\u002Fstrong>를 주당 $135.11의 현금으로 인수하고 있습니다.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">그러나 경쟁은 계속되고 있습니다. \u003Cstrong>존슨앤드존슨 (\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?fid=1&ref=meufz8&cid=139677&tid=2623227\">JNJ\u003C\u002Fa>)\u003C\u002Fstrong>은 지난 분기에 트렘피아를 68% 성장시켰으며, 약 20,000명의 환자가 이미 경구용 건선 치료제 아이코타이드를 시작했습니다.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">다음은 실제 및 예상되는 상위 라인입니다.\u003C\u002Fp>\n\n\n\n\u003Cfigure class=\"wp-block-image size-full\">\u003Cimg width=\"3026\" height=\"2017\" data-public-id=\"images\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e.webp\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_3026,h_2017,c_scale\u002Ff_webp,q_auto\u002Fv1792700279\u002Fimages\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e.webp?_i=AA\" alt=\"\" class=\"wp-post-143739 wp-image-143906\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1792700279\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1792700279\u002Fimages\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e.webp?_i=AA 3026w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1536,h_1024,c_scale\u002Ff_webp,q_auto\u002Fv1792700279\u002Fimages\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e.webp?_i=AA 1536w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_767,h_511,c_scale\u002Ff_webp,q_auto\u002Fv1792700279\u002Fimages\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e.webp?_i=AA 767w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_2048,h_1365,c_scale\u002Ff_webp,q_auto\u002Fv1792700279\u002Fimages\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e.webp?_i=AA 2048w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792700279\u002Fimages\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e.webp?_i=AA 600w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1199,h_799,c_scale\u002Ff_webp,q_auto\u002Fv1792700279\u002Fimages\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e.webp?_i=AA 1199w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1400,h_933,c_scale\u002Ff_webp,q_auto\u002Fv1792700279\u002Fimages\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e.webp?_i=AA 1400w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_299,h_199,c_scale\u002Ff_webp,q_auto\u002Fv1792700279\u002Fimages\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e\u002FTIKR.com_ABBV-AbbVie-Inc.-Revenue_143906d137e.webp?_i=AA 299w\" sizes=\"auto, (max-width: 3026px) 100vw, 3026px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">애브비 (ABBV): 매출, 실제 및 합의 추정치, $10억 달러, 2021–2028 회계연도 (\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">TIKR\u003C\u002Fa>\u003C\u002Fstrong>)\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">매출은 휴미라 하락의 골짜기를 완전히 벗어났으며, 합의치는 향후 2년간 연간 9.7% 성장을 예상하고 있습니다.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">\u003Cstrong>TIKR는 애브비에 대해 30명의 애널리스트를 추적합니다. 몇 명이 \"매수\"라고 말할까요?\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">애브비에 대한 매수, 보유, 매도 등급의 전체 분석과 월가의 매출 및 수익 추정치를 한곳에서 확인하세요. 500,000명 이상의 투자자가 TIKR를 사용하여 이와 같은 주식을 조사합니다. \u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">애브비의 애널리스트 등급 보기\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\">수익이 가격을 따라잡다\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">과거 수치는 우려스러워 보입니다. 애브비는 80.5배의 과거 수익률과 189.8%의 배당금 지급 비율로 거래되고 있으며, 둘 다 인수된 파이프라인 비용으로 인해 부풀려졌습니다. 3분기만 해도 $2.16억 달러의 인수된 IPR&D 및 마일스톤 비용이 발생합니다.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">선행 수치는 더 깔끔한 이야기를 전합니다. 애브비는 18.9배의 선행 수익률로 거래되며, 이는 존슨앤드존슨의 23.2배보다 낮습니다. 또한 합의치는 향후 2년간 EPS가 연간 27.3% 성장할 것으로 예상하는 반면, 존슨앤드존슨은 3.8% 성장할 것으로 예상합니다.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">부채는 트레이드오프로, 애브비가 성장을 계속 인수하면서 순부채는 EBITDA의 2.06배입니다.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">그렇다면 그 EPS 경로는 얼마나 가파를까요?\u003C\u002Fp>\n\n\n\n\u003Cfigure class=\"wp-block-image size-full\">\u003Cimg width=\"3026\" height=\"2017\" data-public-id=\"images\u002FTIKR.com_ABBV-AbbVie-Inc.-EPS-Normalized_1439074e82c\u002FTIKR.com_ABBV-AbbVie-Inc.-EPS-Normalized_1439074e82c.webp\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_3026,h_2017,c_scale\u002Ff_webp,q_auto\u002Fv1792700194\u002Fimages\u002FTIKR.com_ABBV-AbbVie-Inc.-EPS-Normalized_1439074e82c\u002FTIKR.com_ABBV-AbbVie-Inc.-EPS-Normalized_1439074e82c.webp?_i=AA\" alt=\"\" class=\"wp-post-143739 wp-image-143907\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1792700194\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1792700194\u002Fimages\u002FTIKR.com_ABBV-AbbVie-Inc.-EPS-Normalized_1439074e82c\u002FTIKR.com_ABBV-AbbVie-Inc.-EPS-Normalized_1439074e82c.webp?_i=AA 3026w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_1536,h_1024,c_scale\u002Ff_webp,q_auto\u002Fv1792700194\u002Fimages\u002FTIKR.com_ABBV-AbbVie-Inc.-EPS-Normalized_1439074e82c\u002FTIKR.com_ABBV-AbbVie-Inc.-EPS-Normalized_1439074e82c.webp?_i=AA 1536w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_2048,h_1365,c_scale\u002Ff_webp,q_auto\u002Fv1792700194\u002Fimages\u002FTIKR.com_ABBV-AbbVie-Inc.-EPS-Normalized_1439074e82c\u002FTIKR.com_ABBV-AbbVie-Inc.-EPS-Normalized_1439074e82c.webp?_i=AA 2048w\" sizes=\"auto, (max-width: 3026px) 100vw, 3026px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">애브비 (ABBV): 정상화 EPS, 실제 및 합의 추정치, $, 2021–2028 회계연도 (\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">TIKR\u003C\u002Fa>\u003C\u002Fstrong>)\u003C\u002Ffigcaption>\u003C\u002Ffigure>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">제 의견: 루티키주맙은 실망스러웠지만, HS는 애브비의 향후 5년을 결정할 요소가 결코 아니었습니다. 주가는 이미 시장 목표가를 넘어섰기 때문에, 추가 상승 가능성은 아마도 또 다른 가이던스 상향 조정과 아포지의 자산이 프랜차이즈를 2030년대까지 확장할 수 있다는 증명이 필요할 것입니다.\u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">10월 30일의 3분기 실적이 다음 시험대입니다. 스카이리지와 린보크의 20% 이상 성장과 세 번째 매출 가이던스 상향 조정을 주목하세요.\u003C\u002Fp>\n\n\n\n\u003Ch2 id=\"h-so-what-is-abbvie-stock-actually-worth\" class=\"wp-block-heading\">\u003Cstrong>그렇다면 애브비 주식의 실제 가치는 얼마일까요?\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">TIKR를 사용하면 1분도 안 되어 어떤 주식의 미래 가격도 예측할 수 있습니다. TIKR의 가치 평가 모델에 몇 가지 가정을 입력하기만 하면 애브비의 잠재적 가치를 확인할 수 있습니다. 월가 합의 추정치에서 시작하거나, 비즈니스에 대한 자신의 견해를 반영하도록 입력값을 조정하세요. 무료로 사용할 수 있습니다. \u003C\u002Fp>\n\n\n\n\u003Cp class=\"wp-block-paragraph\">\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>ABBV의 가치를 무료로 평가하세요\u003C\u002Fstrong>\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\u003Ch3 id=\"h-disclaimer\" class=\"wp-block-heading\">\u003Cstrong>면책 조항:\u003C\u002Fstrong>\u003C\u002Fh3>\n\n\n\n\u003Cp class=\"wp-block-paragraph\" id=\"h-\">\u003Cem>TIKR의 기사는 TIKR나 저희 콘텐츠 팀의 투자 또는 재정 조언이 아니며, 어떠한 주식을 사거나 팔라는 권고도 아님을 유의하시기 바랍니다. 저희는 TIKR 터미널의 투자 데이터와 애널리스트 추정치를 바탕으로 콘텐츠를 작성합니다. 저희 분석에는 최근 기업 뉴스나 중요한 업데이트가 포함되지 않을 수 있습니다. TIKR는 언급된 주식에 어떠한 포지션도 보유하고 있지 않습니다. 읽어주셔서 감사합니다, 행운을 빕니다!\u003C\u002Fem>\u003C\u002Fp>",872,"ko","\u002Fblog\u002Fabbvie-slips-behind-rivals-as-lutikizumab-hits-31-4-response-in-hs-trial","abbvie-slips-behind-rivals-as-lutikizumab-hits-31-4-response-in-hs-trial","images\u002FABBV-stock_143750c9701\u002FABBV-stock_143750c9701","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792696833\u002Fimages\u002FABBV-stock_143750c9701\u002FABBV-stock_143750c9701.png?_i=AA",{"altText":237,"imageCredit":238},"AbbVie Slips Behind Rivals as Lutikizumab Hits 31.4% Response in HS Trial","Towfiqu barbhuiya from Pexels and pixelshot via Canva",{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":244},"Rexielyn Diaz","rexietikr","author","",[],{"name":246,"slug":247,"role":248,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":249},"David Hanson","davidtikr","editor",[],[251],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},"일반 투자","general-investing","\u002Fblog\u002Fcategory\u002Fgeneral-investing",0,[],{"title":237,"metaDesc":258,"opengraphDescription":258,"twitterTitle":237,"twitterDescription":258},"AbbVie’s lutikizumab hit its Phase 3 goal in hidradenitis suppurativa, but an 8-point edge over placebo underwhelmed.",{"title":237,"description":258,"twitterTitle":237,"twitterDescription":258,"author":240,"articlePublisher":260,"articlePublishedTime":226,"articleModifiedTime":227,"twitterLabel1":261,"twitterData1":262,"ogTitle":237,"ogDescription":258,"ogUrl":232,"ogImage":235,"ogImageWidth":263,"ogImageHeight":264,"ogImageSecureUrl":235,"ogImageAlt":237,"twitterImage":235},"TIKR.com","예상 독서 시간","5 minutes",1200,630,[266,282,299,314,329],{"id":255,"title":267,"date":268,"excerpt":269,"wordCount":270,"uri":271,"slug":272,"cloudinaryAssetId":273,"featuredImageOriginalUrl":274,"featuredImageMetadata":275,"author":277,"categories":279,"relatedPosts":281},"Johnson & Johnson, 4.4% 급등… VARIPULSE Pro, 시술 성공률 100% 기록","2026-10-23 13:40:00","Johnson & Johnson은 4.4% 급등하며 실적 발표 후 하락분을 회복했는데, VARIPULSE Pro 데이터가 MedTech 부문에 드문 승리를 안겨주었기 때문입니다.",913,"\u002Fblog\u002Fjohnson-johnson-jumps-4-4-as-varipulse-pro-hits-100-procedural-success","johnson-johnson-jumps-4-4-as-varipulse-pro-hits-100-procedural-success","images\u002FJNJ-stock_1437491291e\u002FJNJ-stock_1437491291e","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792696575\u002Fimages\u002FJNJ-stock_1437491291e\u002FJNJ-stock_1437491291e.png?_i=AA",{"altText":276},"Johnson & Johnson, 4.4% 급등… VARIPULSE Pro, 시술 성공률 100% 기록",{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":278},[],[280],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":283,"date":284,"excerpt":285,"wordCount":286,"uri":287,"slug":288,"cloudinaryAssetId":289,"featuredImageOriginalUrl":290,"featuredImageMetadata":291,"author":292,"categories":296,"relatedPosts":298},"JPMorgan, DraftKings 목표주가 하향 조정. 여전히 46% 상승 여력 전망","2026-10-23 13:30:00","월가가 목표가를 계속 낮추면서도 계속 '매수'를 외치고 있습니다",826,"\u002Fblog\u002Fjpmorgan-cut-its-draftkings-target-it-still-sees-46-upside","jpmorgan-cut-its-draftkings-target-it-still-sees-46-upside","images\u002FJ.P.-Morgan\u002FJ.P.-Morgan","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792679357\u002Fimages\u002FJ.P.-Morgan\u002FJ.P.-Morgan.png?_i=AA",{"altText":283},{"name":293,"slug":294,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":295},"Roxanna Maglangit","roxtikr",[],[297],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":300,"date":301,"excerpt":302,"wordCount":303,"uri":304,"slug":305,"cloudinaryAssetId":306,"featuredImageOriginalUrl":307,"featuredImageMetadata":308,"author":309,"categories":311,"relatedPosts":313},"UnitedHealth, Optum Health 이익 7억 3,500만 달러로 급증하며 실적 발표 후 9% 상승","2026-10-23 13:20:00","UnitedHealth는 EPS가 61% 급등하고 세 번째로 가이던스를 상향 조정한 후 425달러까지 상승했지만, 매출은 계속 축소되고 있습니다.",914,"\u002Fblog\u002Funitedhealth-climbs-9-since-earnings-as-optum-health-profit-surges-to-735-million","unitedhealth-climbs-9-since-earnings-as-optum-health-profit-surges-to-735-million","images\u002FUNH-stock_14374868532\u002FUNH-stock_14374868532","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792696335\u002Fimages\u002FUNH-stock_14374868532\u002FUNH-stock_14374868532.png?_i=AA",{"altText":300},{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":310},[],[312],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":315,"date":316,"excerpt":317,"wordCount":318,"uri":319,"slug":320,"cloudinaryAssetId":321,"featuredImageOriginalUrl":322,"featuredImageMetadata":323,"author":324,"categories":326,"relatedPosts":328},"AMD 11% 하락, 인텔 1주일 만에 10% 하락… AI 우려에 칩주 하락: \"너무 빨리 너무 크게\"","2026-10-23 13:17:00","두 번의 추한 날들, 그리고 AMD로부터 한마디도 없네요.",715,"\u002Fblog\u002Famd-sinks-11-intel-10-in-a-week-as-ai-fears-hit-chips-too-big-too-fast","amd-sinks-11-intel-10-in-a-week-as-ai-fears-hit-chips-too-big-too-fast","images\u002FAMD_1432925b014\u002FAMD_1432925b014","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792679128\u002Fimages\u002FAMD_1432925b014\u002FAMD_1432925b014.png?_i=AA",{"altText":315},{"name":293,"slug":294,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":325},[],[327],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],{"id":255,"title":330,"date":331,"excerpt":332,"wordCount":333,"uri":334,"slug":335,"cloudinaryAssetId":336,"featuredImageOriginalUrl":337,"featuredImageMetadata":338,"author":339,"categories":341,"relatedPosts":343},"Chevron, Hess Midstream 매각 및 Aphrodite 가스 개발 추진으로 2026년까지 49.5% 상승","2026-10-23 13:10:00","체브론이 3분기로 향하며 기록적인 고점 근처에서 거래되고 있습니다. 100달러의 유가가 30억~40억 달러의 중간 유통 손실과 맞물리는 상황입니다.",980,"\u002Fblog\u002Fchevron-gains-49-5-in-2026-as-it-exits-hess-midstream-and-advances-aphrodite-gas","chevron-gains-49-5-in-2026-as-it-exits-hess-midstream-and-advances-aphrodite-gas","images\u002FCVX-stock_14374763728\u002FCVX-stock_14374763728","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792696158\u002Fimages\u002FCVX-stock_14374763728\u002FCVX-stock_14374763728.png?_i=AA",{"altText":330},{"name":240,"slug":241,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":340},[],[342],{"name":252,"slug":253,"uri":254,"description":243,"postsCount":255},[],[345,365,381,396,411],{"id":255,"title":346,"date":347,"excerpt":348,"wordCount":349,"uri":350,"slug":351,"cloudinaryAssetId":352,"featuredImageOriginalUrl":353,"featuredImageMetadata":354,"author":355,"categories":359,"relatedPosts":364},"IREN 주식, 스페인 캠퍼스 랠리 이후 하루 만에 8% 하락. 월스트리트 목표가가 시사하는 바는 다음과 같습니다","2026-10-23 07:20:00","IREN은 네오클라우드 주식들이 부채 우려로 매도되면서 스페인 캠퍼스 상승분을 단 하루 만에 되돌렸습니다. 300MW 바다호스 라이선스는 용량을 추가하지만, IREN은 아직 데이터센터를 담보로 한 대출을 마무리하지 못했습니다. 애널리스트들의 12개월 목표가가 시사하는 바는 다음과 같습니다.",908,"\u002Fblog\u002Firen-stock-fell-8-in-a-day-after-its-spain-campus-rally-heres-what-wall-streets-targets-imply","iren-stock-fell-8-in-a-day-after-its-spain-campus-rally-heres-what-wall-streets-targets-imply","images\u002F18_14404989fa4\u002F18_14404989fa4","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792717505\u002Fimages\u002F18_14404989fa4\u002F18_14404989fa4.png?_i=AA",{"altText":346},{"name":356,"slug":357,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":358},"Wiltone Asuncion","wiltonetikr",[],[360],{"name":361,"slug":362,"uri":363,"description":243,"postsCount":255},"주식 리뷰","reviews","\u002Fblog\u002Fcategory\u002Freviews",[],{"id":255,"title":366,"date":367,"excerpt":368,"wordCount":369,"uri":370,"slug":371,"cloudinaryAssetId":372,"featuredImageOriginalUrl":373,"featuredImageMetadata":374,"author":376,"categories":378,"relatedPosts":380},"Hims & Hers 주가, 최대 규모 남성 건강 제품 출시 이후 거의 움직이지 않아. 11월 9일이 보여준 것은 다음과 같다","2026-10-23 07:15:00","Hims & Hers는 10월 21일에 주사용 및 경구용 테스토스테론을 출시했으며, 그 이후 주가는 거의 움직이지 않았습니다. 경영진은 8월에 이 출시를 약속했으며, 테스토스테론이 1억 달러의 연간화된 페이스(run-rate)에 도달할 것으로 예상합니다. 12월 31일 DEA 마감일과 11월 9일 실적 발표가 다음 시험대가 될 것입니다.",977,"\u002Fblog\u002Fhims-hers-stock-has-barely-moved-since-its-biggest-mens-health-launch-heres-what-november-9-has-to-show","hims-hers-stock-has-barely-moved-since-its-biggest-mens-health-launch-heres-what-november-9-has-to-show","images\u002F17_144048ee756\u002F17_144048ee756","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792717512\u002Fimages\u002F17_144048ee756\u002F17_144048ee756.png?_i=AA",{"altText":375},"Hims & Hers 주가, 최대 규모 남성 건강 제품 출시 이후 거의 움직이지 않아. 11월 9일이 보여준 것은 다음과 같다",{"name":356,"slug":357,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":377},[],[379],{"name":361,"slug":362,"uri":363,"description":243,"postsCount":255},[],{"id":255,"title":382,"date":383,"excerpt":384,"wordCount":385,"uri":386,"slug":387,"cloudinaryAssetId":388,"featuredImageOriginalUrl":389,"featuredImageMetadata":390,"author":391,"categories":393,"relatedPosts":395},"브로드컴 주가 4% 하락, 반도체주 하락세 속 10년 만의 VMware 인수 후 며칠 지나... 월가의 목표가가 말하는 것","2026-10-23 07:10:00","브로드컴은 10월 22일 반도체주가 하락에 따라 4.31% 하락했으며, 이는 일본에서 첫 10년간 VM웨어 계약을 체결한 지 며칠 지나지 않아 발생한 일입니다. 이익 예측은 계속 상승하고 있지만, 주가는 2월 수준보다 낮게 거래되고 있습니다.",903,"\u002Fblog\u002Fbroadcom-stock-fell-4-as-chip-stocks-slid-days-after-a-10-year-vmware-deal-heres-what-wall-streets-targets-say","broadcom-stock-fell-4-as-chip-stocks-slid-days-after-a-10-year-vmware-deal-heres-what-wall-streets-targets-say","images\u002F16-1_14404727574\u002F16-1_14404727574","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792717515\u002Fimages\u002F16-1_14404727574\u002F16-1_14404727574.png?_i=AA",{"altText":382},{"name":356,"slug":357,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":392},[],[394],{"name":361,"slug":362,"uri":363,"description":243,"postsCount":255},[],{"id":255,"title":397,"date":398,"excerpt":399,"wordCount":400,"uri":401,"slug":402,"cloudinaryAssetId":403,"featuredImageOriginalUrl":404,"featuredImageMetadata":405,"author":406,"categories":408,"relatedPosts":410},"Nebius 주식이 35억 달러 Citi 시설 발표 당일 7% 하락했습니다. AI 칩 부족이 얼마나 지속될지에 대한 CEO의 발언은 다음과 같습니다.","2026-10-23 07:00:00","Nebius는 10월 22일 35억 달러 규모의 364일 만기 Citi 시설을 발표한 날 7.23% 하락했으며, CoreWeave와 IREN은 2026년 최저치로 떨어졌습니다. 9월에 해당 회사의 CEO는 AI 컴퓨팅 공급이 수요를 따라잡는 대략적인 시기를 언급했습니다. 그 시기는 새로운 거래의 투자 회수 기간과 가깝습니다.",784,"\u002Fblog\u002Fnebius-stock-fell-7-the-day-it-announced-a-3-5-billion-citi-facility-heres-what-its-ceo-said-about-how-long-the-ai-chip-shortage-lasts","nebius-stock-fell-7-the-day-it-announced-a-3-5-billion-citi-facility-heres-what-its-ceo-said-about-how-long-the-ai-chip-shortage-lasts","images\u002F14-1_144045ee128\u002F14-1_144045ee128","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792717438\u002Fimages\u002F14-1_144045ee128\u002F14-1_144045ee128.png?_i=AA",{"altText":397},{"name":356,"slug":357,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":407},[],[409],{"name":361,"slug":362,"uri":363,"description":243,"postsCount":255},[],{"id":255,"title":412,"date":413,"excerpt":414,"wordCount":415,"uri":416,"slug":417,"cloudinaryAssetId":418,"featuredImageOriginalUrl":419,"featuredImageMetadata":420,"author":421,"categories":423,"relatedPosts":425},"머크, 유럽에서 키트루다의 방광암 적응증 확대 승인. ESMO 데이터에서 보여야 할 것은 다음과 같습니다","2026-10-22 21:00:00","유럽이 키트루다와 패드세브 병용 요법을 시스플라틴 적격성과 무관하게 방광암 환자로 확대했습니다. 3일 후, ESMO에서 머크의 암 백신이 연구 책임자가 설정한 기준을 통과하는지 여부가 공개됩니다.",836,"\u002Fblog\u002Fmerck-won-a-wider-eu-bladder-cancer-label-for-keytruda-heres-what-its-esmo-data-needs-to-show","merck-won-a-wider-eu-bladder-cancer-label-for-keytruda-heres-what-its-esmo-data-needs-to-show","images\u002F13-7_1439568ebea\u002F13-7_1439568ebea","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_600,h_400,c_scale\u002Ff_webp,q_auto\u002Fv1792700551\u002Fimages\u002F13-7_1439568ebea\u002F13-7_1439568ebea.png?_i=AA",{"altText":412},{"name":356,"slug":357,"role":242,"roleTitle":243,"biography":243,"avatar":243,"socialMediaLinks":422},[],[424],{"name":361,"slug":362,"uri":363,"description":243,"postsCount":255},[]]